Published in Glob J Health Sci on August 14, 2014
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med (2007) 12.73
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol (2011) 4.67
Cancer incidence and mortality in Iran. Ann Oncol (2008) 3.34
Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev (2005) 2.88
Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2007) 2.33
A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol (2007) 2.09
Systematic overview of cost-utility assessments in oncology. J Clin Oncol (2000) 2.02
Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant (2001) 1.92
Health state utilities for metastatic breast cancer. Br J Cancer (2006) 1.50
Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer (2007) 1.40
Health related quality of life in different states of breast cancer. Qual Life Res (2007) 1.24
Normative data of bone Mineral Density in healthy population of Tehran, Iran: a cross sectional study. BMC Musculoskelet Disord (2005) 1.18
Trastuzumab: hopes and realities. Lancet Oncol (2002) 1.07
Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann Oncol (2007) 0.99
Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model. Pharmacoeconomics (2007) 0.98
The costs of caring: Who pays? Who profits? Who panders? Hastings Cent Rep (2006) 0.95
Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy (2008) 0.92
Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. Oncologist (2012) 0.91
The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial. Value Health (2011) 0.85
Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence. Pharmacoeconomics (2011) 0.85
The Direct Medical Costs of Breast Cancer in Iran: Analyzing the Patient's Level Data from a Cancer Specific Hospital in Isfahan. Int J Prev Med (2013) 0.85
An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia. Biomedica (2014) 0.80
Detection of mixed Plasmodium falciparum & P. vivax infections by nested-PCR in Pakistan, Iran & Afghanistan. Indian J Med Res (2010) 1.93
Spectrum of clinical disease in a series of hospitalized HIV-infected patients from southeast of Iran. Saudi Med J (2006) 1.65
Trends of fatal road traffic injuries in Iran (2004-2011). PLoS One (2013) 1.62
Evaluation of the efficacy of ribavirin therapy on survival of Crimean-Congo hemorrhagic fever patients: a case-control study. Jpn J Infect Dis (2009) 1.54
Molecular characterization of Plasmodium vivax clinical isolates in Pakistan and Iran using pvmsp-1, pvmsp-3alpha and pvcsp genes as molecular markers. Parasitol Int (2009) 1.16
Development of evidence-based health policy documents in developing countries: a case of Iran. Glob J Health Sci (2014) 1.01
High prevalence of the 437G mutation associated with sulfadoxine resistance among Plasmodium falciparum clinical isolates from Iran, three years after the introduction of sulfadoxine-pyrimethamine. Int J Infect Dis (2010) 0.92
Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users. Hepat Mon (2013) 0.91
High prevalence of alpha 1 antitrypsin phenotypes in viral hepatitis B infected patients in Iran. Hepatol Res (2005) 0.88
Family medicine in Iran: facing the health system challenges. Glob J Health Sci (2014) 0.88
The risk of transmission of Crimean-Congo hemorrhagic fever virus from human cases to first-degree relatives. Jpn J Infect Dis (2008) 0.87
Demand for medical care in the urban areas of Iran: an empirical investigation. Health Econ (2008) 0.86
Psychometric properties of the Persian version of the World Health Organization's quality of life questionnaire (WHOQOL-100). Arch Iran Med (2011) 0.85
Efficacy of applying self-assessment of larviciding operation, Chabahar, Iran. Malar J (2012) 0.84
The road traffic crashes as a neglected public health concern; an observational study from Iranian population. Traffic Inj Prev (2014) 0.83
Effects of parental education level and economic status on the needs of families of hearing-impaired children in the aural rehabilitation program. Iran J Otorhinolaryngol (2013) 0.82
Association between spasticity and the level of motor function with quality of life in community dwelling Iranian young adults with spastic cerebral palsy. Med J Islam Repub Iran (2012) 0.82
Geographical mapping and Bayesian spatial modeling of malaria incidence in Sistan and Baluchistan province, Iran. Asian Pac J Trop Med (2011) 0.81
Main determinants of catastrophic health expenditures: a Bayesian logit approach on Iranian household survey data (2010). Glob J Health Sci (2015) 0.81
Comparison of auditory temporal resolution between monolingual Persian and bilingual Turkish-Persian individuals. Int J Audiol (2013) 0.79
Asymmetric Information in Iranian's Health Insurance Market: Testing of Adverse Selection and Moral Hazard. Glob J Health Sci (2015) 0.78
Relation between Voice Handicap Index (VHI) and disease severity in Iranian patients with Parkinson's disease. Med J Islam Repub Iran (2012) 0.78
Health Care Expenditure and GDP in Oil Exporting Countries: Evidence From OPEC Data, 1995-2012. Glob J Health Sci (2015) 0.78
Intra-familial Transmission of Hepatitis B virus Infection in Zahedan. Iran Red Crescent Med J (2013) 0.77
An Exploration of the Role of Hospital Committees to Enhance Productivity. Glob J Health Sci (2015) 0.75
Assessing the Factors Associated With Iran's Intra-Industry Trade in Pharmaceuticals. Glob J Health Sci (2015) 0.75
The Relationship between the Behavioral Hearing Thresholds and Maximum Bilirubin Levels at Birth in Children with a History of Neonatal Hyperbilirubinemia. Iran J Otorhinolaryngol (2013) 0.75
Work-related accidents among the Iranian population: a time series analysis, 2000-2011. Int J Occup Environ Health (2015) 0.75
Main Determinants of Supplementary Health Insurance Demand: (Case of Iran). Glob J Health Sci (2015) 0.75
Test-retest reliability of Motricity Index strength assessments for lower extremity in post stroke hemiparesis. Med J Islam Repub Iran (2012) 0.75
Cost effectiveness analysis of Avonex and CinnoVex in Relapsing Remitting MS. Glob J Health Sci (2014) 0.75
A Study of Comparative Advantage and Intra-Industry Trade in the Pharmaceutical Industry of Iran. Glob J Health Sci (2015) 0.75
Application of the Activity-Based Costing Method for Unit-Cost Calculation in a Hospital. Glob J Health Sci (2015) 0.75
Factors Affecting Health Care Utilization in Tehran. Glob J Health Sci (2015) 0.75